Novo Integrated Sciences, Inc.
NVOS Healthcare Medical Care Facilities
Novo Integrated Sciences, Inc.’s revenue for fiscal 2024 (year ended August 2024) was $13.3 million, up 5.75% from fiscal 2023. Revenue growth for five consecutive years.
Follow NVOS
Novo Integrated Sciences, Inc. (NVOS) EV/Sales
As of 15 October 2026, Novo Integrated Sciences, Inc. (NVOS) trades at a EV/Sales of 0.0×. Over the past ten years it has ranged from 0.0× (May 2017) to 561× (November 2018); the current reading is higher than 31% of that period. That is below the Medical Care Facilities industry median of 1.3× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | 0.4× | (65.77%) |
| FY2023 | 1.2× | (73.30%) |
| FY2022 | 4.5× | (11.87%) |
| FY2021 | 5.1× | (56.04%) |
| FY2020 | 11.6× | (86.42%) |
| FY2019 | 85.4× | (63.51%) |
| FY2018 | 234× | 268.29% |
| FY2017 | 63.5× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Aug 2024 | 0.4× | (71.03%) |
| May 2024 | 1.4× | 67.71% |
| Feb 2024 | 0.8× | (43.51%) |
| Nov 2023 | 1.5× | 24.69% |
| 29 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CANOQ Cano Health, Inc. compare | 0.0× |
| NIVF NewGenIvf Group Limited compare | n/m |
| BMGL Basel Medical Group Ltd compare | n/m |
| NVOS Novo Integrated Sciences, Inc. | 0.0× |
| MODVQ ModivCare Inc. compare | 0.4× |
| RHEP Adcare Health Systems Inc compare | 0.5× |
| BACK IMAC Holdings, Inc. compare | 0.8× |
| SYRA Syra Health Corp. compare | 1.3× |
| IONM Assure Holdings Corp. compare | 165× |
| Medical Care Facilities industry median | 1.3× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)